How a quiet iOS update confirmed what I've been writing for a year and what it means for companies, services, and chips. Executive Summary Apple has quietly partnered with SpaceX and T-Mobile to bring Starlink satellite messaging directly to the iPhone through a recent software update, breaking
Thesis Update — The Track Holds Through May, But Stronger. The Supply Build Is Now Three-Sided. The Update in One Line Through May 2026, the 1927 overlay is holding month by month, but running hotter, because AI is a more powerful leadership engine than radio ever was, and because the
The Lowest-Cost Chronic-Disease Aggregation Platform Meets a Structurally Engineered Short Squeeze ★ MAJOR BUY RECOMMENDATION ★ Status: Pre-Catalyst (Nasdaq compliance deadline: June 30, 2026) Executive Summary We rate Vivos Therapeutics (NASDAQ: VVOS) a MAJOR BUY on the strength of two independent and coequal pillars, each of which would justify
In 2024, 12th-grade NAEP math and reading scores hit their lowest levels ever recorded. The usual suspects lined up immediately — pandemic learning loss, screen time, chronic absenteeism, underfunding. All plausible. But the decline started well before COVID, and none of those explanations account for a pattern hiding in plain
The Companies Powering the Buildout and Why the Smartest Money on Wall Street Is Crowding In A nine-company infrastructure portfolio including AmpliTech Group (NASDAQ: AMPG) as a featured essential play and positioned for the largest capital-deployment cycle in modern history. Executive Summary The artificial-intelligence buildout has become
★ MAJOR BUY RECOMMENDATION ★ AmpliTech Group (NASDAQ: AMPG) The Forgotten Winner of the Satellite-to-Phone Trade PART I — Recommendation: MAJOR BUY (AMPG) This is a major buy recommendation on a totally overlooked stock. Wall Street is staring at the wrong end of the satellite-to-cell revolution — fixated on Starlink&
How ReBalU's endogenous butyrate and DHA systematically influence 18 validated longevity genes, and how the test/treat/retest platform compensates for the genetic insufficiencies that determine how fast you age. This is Part Two of a two-part series on the ReBalU protocol and longevity biology. Part One
Horizon: 24 Months (through May 2028) | Rating: Strategic Buy / Acquisition Candidate Current Price: $5.23 | 24-Month Blended Target: $28.40 | Upside: +443% Strategic Takeout Range: $13.00 – $32.00 | Standalone Discounted Range: $41 – $70 1. Executive Summary AmpliTech Group is the only US supplier of a commercial-grade 64T64R
New research from the Buck Institute finally explains why some people age dramatically slower. A precision nutrition protocol called ReBalU is engineered to give everyone else the same advantage. This is Part One of a two-part series on the ReBalU protocol and longevity biology. Part Two goes deep on
Investment Highlights * Trading at Just $1.00 per Share — Extraordinary asymmetric entry point relative to FY2027/FY2028 forecast trajectory * Pure-Play Agentic AI Business Model — AI ERA operates UFilm.ai and licenses its proprietary agentic AI script-making technology to UFlix.ai (and intends to license to additional platforms), while
Executive Summary Human papillomavirus is one of the most common sexually transmitted infections. Almost all sexually active people encounter it at some point, usually without symptoms and usually with natural immune clearance. Yet the clinical burden is enormous. Persistent infection with carcinogenic HPV types leads to cervical precancer and cancer
This is Part Three of a three-part series on agentic AI and the U.S. economy. Part One laid out the macro thesis and scenario framework — why mainstream forecasts are structurally wrong and what the services-first math actually produces. Part Two examined the 1923–29 Roaring Twenties analog